Green Griffith partners, Christopher Griffith and Emer Simic, were invited to attend the 7th Annual Pharma IPR Conference in Mumbai, India.
Chris chaired day one of the conference concerning U.S. patent law and presented on “Latest Developments: Federal Courts and PTAB.” Chris’ presentation specifically addressed recent developments concerning patent-eligibility under Section 101 in the context of pharma patents and the application of IPR estoppel at PTAB and in US patent litigation. Since 2012, the UBM Pharma IPR Conference has focused on importance of Intellectual Property in pharma, and how global IP considerations affect the business objectives of Indian pharma companies.
